1[1]Baldwin S J, Clarke S E, Chenery R J. Characterization of the cytochrome P450 enzymes involved in the in vitro metablism of rosiglitazone[J]. Br J Clin Pharmacol, 1999,48(3):424-432. 被引量：1
2[2]Jha R J. Thiazoldinedione-the new insulin enhancer[J]. Clin Exp Hypertens, 1999, 21:157-166. 被引量：1
3[3]Zhu Y. Structural organization of mouse peroxisome proliferator activiating receptorγ(mPPAR-γ) gene-alternative promotor use and different splicing yield mPPAR-γ isoforms[J]. Proc Natl Acad Sci USA, 1995,92:7921. 被引量：1
4[4]Hotamisligli G S. IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesity-induced insulin resistance[J]. Science, 1996, 271:665. 被引量：1
5[5]Balfour J A. Rosiglitazone [J]. Drugs, 1999,57: 921-931. 被引量：1
6[6]Saltiel A R, Olefsky J M. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes[J]. Diabetes, 1996,45:1661. 被引量：1
7[7]Goetze S, Xi X P, Kawano Y, et al. TNF-alpha-induced nigration of vascular smooth muscle cells is MAPK dependent[J]. Hypertension, 1999, 33(1): 183-189. 被引量：1
8[8]Nolan J J, Jones N P, Patwardhan R, et al. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus [J]. Diabet Med, 2000,17:287-294. 被引量：1
9[9]Li A C, Brown K K, Slivestre M J, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit devel opment of atherosclerosis in LDL receptor-deficient mice[J]. J Clin Invest, 2000,106(4):523-531. 被引量：1
10[10]Goldstein B J. Rosiglitazone[J]. Int J Clin Pract, 2000,54(5):333-337. 被引量：1
